From the director … : warning label advised for hyperactivity drugs

medicines prescribed for attention deficit hyperactivity disorder (ADHD) were the topic of discussion at the February meeting of the FDA's medicine Safety and Advisory Committee, upon which I serve as the consumer representative. The agency's bear upon was sparked by reports of unlooked for death, heart attack, and other cardiovascular facts occurring in people who take remedys for ADHD. Adderall, Concerta, Strattera and Ritalin are the greatest in quantity prescribed. An estimated 2.5 to 3 million children and 15 million adults take these physics In recent years there has been considerable debate about whether ADHD, a non-medical condition, is over-diagnosed and over-treated with drugs

In a surprise propel the FDA advisory committee vot by means of a narrow margin (8 to 7) to require a black receptacle warning about possible cardiovascular risks upon the labeling for all ADHD medicines FDA staffers Dr. Thomas Laughren, director of the Division of Psychiatry proceedss and Dr. Robert Temple, director of the office of medical policy, have the appearanceed especially perturbed by the promised After the meeting they opined that based upon available evidence the current labeling was adequate and cautioned that a black receptacle warning could scare people away from a physic that could benefit them. Their squeeze outed reticence to require a stronger warning is, I believe, an indication that the FDA is below heavy pressure from doctors who treat mental health and behavioral disorders with remedys to go slow on imposing fresh and stronger drug warnings.

The FDA appears scarred through the intense criticism from medical organizations, of the like kind as the American Psychiatric Association, that followed the agency's 2004 decision to require a black-box warning upon antidepressant drug labels about the risks of suicide and suicidal contemplations among children and adolescents. Child psychiatrists and others in the medical community remain critical of that FDA's decision which they say was based upon insufficient evidence and has frightened tribe away from helpful treatment with antidepressants.

According to the agency, ADHD remedy prescription for adults have almost doubled in the years 2002 to 2005 Thomas R Fleming, PhD a committee member and bio-statistician at the University of Washington, used FDA's analysis of reports of cardiovascular adverse circumstances to calculate that the cardiovascular risks of ADHD remedys could be equal to or greater than those of the painkillers Vioxx and Bextra which are no longer marketed.

While acknowledging that more safety data are emergencyed to conclusively prove, or disprove, the severity of cardiovascular risks related to ADHD physic use, those at the committee meeting favoring the fresh warning (myself included) argued that it would be inequitable for the FDA not to act now. Steve Nissen, MD acting director of cardiology at Cleveland Clinic, cautioned that no matter in what manner small the risk, the effects of severe cardiovascular side issues can be profound. "I want to cause people's hands to quake a little," Nissen said of the precautionary issue a black box warning would hopefully have upon doctor's prescribing practices. I moveed that given the uncertainty above the cardiovascular safety of ADHD physics the FDA has an ethical what one ought to do to warn the millions of adults and children commonly taking ADHD drugs, or who might be prescribed the remedys in the future, that the physics may be deadly.

The FDA's reticence to require stronger warnings upon ADHD drugs was buoyed when a meeting of the pediatric advisory committee in late March commended against a black box warning for children. At that meeting, psychopharmacologists and other prompts expressed concern that such a hardy warning might do more harm then good--apparently music to Dr Temple's ears who declared the agency is likely to tread in the steps of the pediatric committee's advice.

The FDA has said it will make its final decision about any ADHD physic label changes after consideration of the conflicting advice from the advisory committees. I believe the FDA should disregard the advice from a certain quantity of in the clinical community not to require a black-box warning about the cardiovascular risks of ADHD medicines Medical paternalism is unfortunate enough when practiced through doctors--but it is absolutely unacceptable in FDA decision-making about the public's safety.

COPYRIGHT 2006 Center for Medical Consumer Inc.

COPYRIGHT 2006 Gale Group